Clinical Trials
CSL Behring begins pediatric Phase III hemophilia B study of rIX-FP
CSL Behring has commenced the patient enrollment in pivotal pediatric Phase III hemophilia B study of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP). The study is designed to assess rIX-FP's...
Clinical Trials
GlycoMimetics completes enrollment in Phase 2 study of GMI-1070
Clinical-stage biotechnology company GlycoMimetics has completed patient enrollment for the Phase 2 sickle cell disease study evaluating GMI-1070. Hospitalized sickle cell disease patients experiencing vaso-occlusive crisis were examined for the efficacy, safety and pharmacokinetics...
Clinical Trials
Kiadis Pharma raises fund for Phase II study of ATIR
Kiadis Pharma has raised EUR10m in a financing round to conduct Phase II study of a cell based medicinal product candidate, ATIR, and to prepare a Phase II/III study. ATIR Phase II study is...
Clinical Trials
Pfizer Phase 3 fibromyalgia study of pregabalin meets primary endpoint
Pfizer Phase III study of pregabalin controlled-release (CR) formulation has met primary endpoint of time to loss of therapeutic response (LTR), in fibromyalgia patients. The primary endpoint of the placebo-controlled, multi-center study was achieved...
Clinical Trials
Idera completes patient enrollment in Phase 2 trial of IMO-3100
Idera Pharmaceuticals has concluded enrolling patients in double-blind, placebo-controlled Phase 2 trial assessing IMO-3100 in psoriasis patients. The study randomized 44 patients suffering from moderate to severe plaque psoriasis with IMO-3100 at 0.16mg/kg or...
Clinical Trials
Novavax pandemic influenza vaccine meets endpoints in two Phase 1 trials
Novavax A/H5N1 avian influenza vaccine candidate has met safety and immunogenicity endpoints in two Phase 1 clinical trials. The trials achieved the primary objectives by displaying the safety and immunogenicity of different doses of...
Clinical Trials
Hybrigenics starts phase II clinical trial of inecalcitol in chronic lymphocytic leukemia
Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments against proliferative diseases, today announces the start of a phase II clinical trial of oral inecalcitol in...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read